
BOOST Pharma BOOST Pharma AB is a clinical-stage biotechnology company developing novel, first-in-class off-the-shelf stem cell therapies for rare, debilitating pediatric skeletal diseases. The Company’s lead program, BT-101, is an allogeneic mesenchymal stem cell therapy for osteogenesis imperfecta, a severe rare bone disorder, and has received Orphan Drug Designation in both the U.S. and Europe. BT-101 is currently advancing toward a planned Phase III clinical trial. BOOST is backed by a strong syndicate of life-science investors, including Industrifonden, KD ventures, and Sound Bioventures, who support the Company’s strategy focused on high-impact science, capital-efficient development, and clear pathways to market. The Company is led by a team with deep experience in biotech innovation, clinical execution, and value creation. Therapeutic Developer

BOOST Pharma

BOOST Pharma AB is a clinical-stage biotechnology company developing novel, first-in-class off-the-shelf stem cell therapies for rare, debilitating pediatric skeletal diseases. The Company’s lead program, BT-101, is an allogeneic mesenchymal stem cell therapy for osteogenesis imperfecta, a severe rare bone disorder, and has received Orphan Drug Designation in both the U.S. and Europe. BT-101 is currently advancing toward a planned Phase III clinical trial. BOOST is backed by a strong syndicate of life-science investors, including Industrifonden, KD ventures, and Sound Bioventures, who support the Company’s strategy focused on high-impact science, capital-efficient development, and clear pathways to market. The Company is led by a team with deep experience in biotech innovation, clinical execution, and value creation.

Therapeutic Developer